Cardiff Oncology (TROV) Stock Price, News & Analysis

Company Overview

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Key Stats

• Today's Range: $2.24 to $2.43
• 50-Day Range: $1.19 to $24.71
• 52-Week Range: $0.70 to $3.46
• Volume: 810,424 shs
• Average Volume: 648,892 shs
• Market Capitalization: $24.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TROV Stock Analysis - Frequently Asked Questions

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:TROV) released its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%.

When did Cardiff Oncology's stock split?

Shares of Cardiff Oncology reverse split on Wednesday, February 20th 2019.The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA Royalty (XOMA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Bristol Myers Squibb (BMY), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 2/27/2020
• Today: 10/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TROV
• CIK: 1213037
• Web: www.trovagene.com
• Phone: (858) 952-7570
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.41 million
• Net Margins: -3,688.31%
• Pretax Margin: N/A
• Return on Equity: -202.00%
• Return on Assets: -122.92%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 2.37
• Quick Ratio: 2.37

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 98.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.94 per share
• Price / Book: 2.38

Miscellaneous

• Outstanding Shares: 11,011,000
• Free Float: N/A
• Market Cap: $24.66 million
• Optionable: Not Optionable
• Beta: 1.04